Perspective Therapeutics, Inc. is a radiopharmaceutical development company that is developing advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides. It is also developing imaging diagnostics that incorporate the same targeting peptides, which provide the opportunity to personalize treatment and optimize patient outcomes. This theranostic approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-α-NET) programs have entered Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several academic institutions. It has also developed a 212Pb generator to secure key isotopes for clinical trial and commercial operations.

• Revenue in USD (TTM)-3.68m
• Net income in USD-53.78m
• Incorporated2018
• Employees116.00

• Location
  Perspective Therapeutics Inc2401 Elliott Avenue, Suite 320SEATTLE 98121United StatesUSA
• Phone+1 (206) 676-0900
• Fax+1 (302) 636-5454
• Websitehttps://www.perspectivetherapeutics.com/